EWTX
Edgewise Therapeutics, Inc.
$32.82
+4.42%
$3.4B
No data for this timeframe.
Vol
Market Cap$3.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders8 funds
Inst. Value$283.9M
Inst. Activity6 buys / 0 sells
Insider Activity0B / 5S
Insider Net $-$4.0M
SEC Reports4
Recent Activity
May 7, 2026
SEC
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenu
8-K — Impact 4/10
May 7, 2026
earnings_calendar
EWTX Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
Insider
Donovan Joanne M. sold 50,000 shares
CMO @ $7.08 ($354.0K)
May 5, 2026
Insider
Donovan Joanne M. sold 50,000 shares
CMO @ $38.57 ($1.9M)
May 5, 2026
Insider
Donovan Joanne M. sold 50,000 shares
CMO @ $0.00 ($0.00)
Apr 23, 2026
SEC
Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electi
DEFA14A — Impact 2/10
Mar 27, 2026
SEC
Joanne Donovan, an officer of Edgewise Therapeutics, filed a Form 144 to notify intent to sell up to 71,588 shares of co
144 — Impact 3/10
Inst.
MORGAN STANLEY — DOUBLED
2,910,881 shares ($72.2M)
Price Targets
$43.67
+33.0% upside
Strong Buy
Current $32.82
Low $20.00
Median $45.50
High $52.00
12 analysts
$20.00
$52.00
Analyst Ratings
6Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 17, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 17, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Feb 27, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.48 ▲ +2.2% | $-0.58 — $-0.43 | -42% YoY | 10 |
| Next Q | $-0.52 ▲ +1.0% | $-0.62 — $-0.42 | -33% YoY | 10 |
| Current FY | $-2.03 ▲ +1.8% | $-2.34 — $-1.75 | -25% YoY | 10 |
| Next FY | $-2.33 | $-3.07 — $-1.73 | -15% YoY | 9 |
Latest Reports
NEUTRAL
8-K
4/10
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenu
May 7, 2026
NEUTRAL
DEFA14A
2/10
Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electi
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $120.9M | — |
| MORGAN STANLEY | $72.2M | DOUBLED |
| BANK OF AMERICA CORP | $36.6M | DOUBLED |
| NORGES BANK | $18.6M | NEW |
| FMR LLC | $17.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 5, 2026 | Donovan Joanne | M | $354.0K |
| May 5, 2026 | Donovan Joanne | SELL | $1.9M |
| May 5, 2026 | Donovan Joanne | M | $0.00 |
| May 4, 2026 | Donovan Joanne | SELL | $163.7K |
| Apr 1, 2026 | Fox Jonathan | A | $0.00 |
8 institutional holders with $283.9M total value (11,439,286 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,871,624 | $120.9M | 42.6% | — |
| 2 | MORGAN STANLEY | 2,910,881 | $72.2M | 25.4% | DOUBLED +234.7% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,474,797 | $36.6M | 12.9% | DOUBLED +359.2% |
| 4 | NORGES BANK | 751,355 | $18.6M | 6.6% | NEW |
| 5 | FMR LLC | 692,955 | $17.2M | 6.1% | DOUBLED +173.5% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 611,384 | $15.2M | 5.3% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 75,442 | $1.9M | 0.7% | ADD +78.8% |
| 8 | TWO SIGMA INVESTMENTS, LP | 50,848 | $1.3M | 0.4% | ADD +93.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 869,678 | 2,910,881 | +234.7% | $72.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 321,132 | 1,474,797 | +359.2% | $36.6M | 2025-Q4 |
| NORGES BANK | NEW | — | 751,355 | — | $18.6M | 2025-Q4 |
| FMR LLC | DOUBLED | 253,325 | 692,955 | +173.5% | $17.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 42,196 | 75,442 | +78.8% | $1.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 26,266 | 50,848 | +93.6% | $1.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 254,429 | 321,132 | +26.2% | $5.2M | 2025-Q3 |
| FMR LLC | TRIM | 470,717 | 253,325 | -46.2% | $4.1M | 2025-Q3 |
| UBS Group AG | TRIM | 170,982 | 114,128 | -33.3% | $1.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 26,266 | — | $426.0K | 2025-Q3 |
| NORGES BANK | EXIT | 47,755 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 408,997 | 727,714 | +77.9% | $9.5M | 2025-Q2 |
| FMR LLC | DOUBLED | 186,023 | 470,717 | +153.0% | $6.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 695,426 | 254,429 | -63.4% | $3.3M | 2025-Q2 |
| UBS Group AG | TRIM | 243,896 | 170,982 | -29.9% | $2.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 47,755 | — | $626.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 34,999 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 92,066 | 243,896 | +164.9% | $5.4M | 2025-Q1 |
| FMR LLC | TRIM | 248,036 | 186,023 | -25.0% | $4.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 598,651 | 181,178 | -69.7% | $4.0M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 131,667 | 34,999 | -73.4% | $770.0K | 2025-Q1 |
| NORGES BANK | EXIT | 47,755 | 0 | -100.0% | $0.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 22,357 | 33,918 | +51.7% | $905.6K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 27,465 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 522,086 | — | $13.9M | 2024-Q3 |
2 unique insiders with 5 transactions. Net insider value: -$4.0M ($0.00 bought, $4.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Donovan Joanne M. | CMO | M | 50,000 | $7.08 | $354.0K |
| May 5, 2026 | Donovan Joanne M. | CMO | SELL | 50,000 | $38.57 | $1.9M |
| May 5, 2026 | Donovan Joanne M. | CMO | M | 50,000 | $0.00 | $0.00 |
| May 4, 2026 | Donovan Joanne M. | CMO | SELL | 5,230 | $31.29 | $163.7K |
| Apr 1, 2026 | Fox Jonathan C | Director | A | 339 | $0.00 | $0.00 |
| Apr 1, 2026 | Donovan Joanne M. | CMO | M | 28,662 | $7.08 | $202.9K |
| Apr 1, 2026 | Donovan Joanne M. | CMO | SELL | 28,662 | $32.31 | $926.1K |
| Apr 1, 2026 | Donovan Joanne M. | CMO | M | 28,662 | $0.00 | $0.00 |
| Mar 31, 2026 | Donovan Joanne M. | CMO | M | 21,338 | $7.08 | $151.1K |
| Mar 31, 2026 | Donovan Joanne M. | CMO | SELL | 21,338 | $32.12 | $685.3K |
| Mar 31, 2026 | Donovan Joanne M. | CMO | M | 21,338 | $0.00 | $0.00 |
| Mar 27, 2026 | Donovan Joanne M. | CMO | SELL | 9,623 | $30.98 | $298.1K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
4/10
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~
May 7, 2026
NEUTRAL
DEFA14A
2/10
Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on thr
Apr 23, 2026
NEUTRAL
144
3/10
Joanne Donovan, an officer of Edgewise Therapeutics, filed a Form 144 to notify intent to sell up to
Mar 27, 2026
NEUTRAL
8-K
4/10
Edgewise Therapeutics reported Q4 2025 financial results with a net loss of $50.2 million and $530.1
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 18 analysts: 6 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$43.67 mean target
+33.0% upside
Strong Buy (1.58)
$20.00 Low
$52.00 High
| Metric | Value |
|---|---|
| Current Price | $32.82 |
| Target Low | $20.00 |
| Target Mean | $43.67 |
| Target Median | $45.50 |
| Target High | $52.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.58) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.48 | $-0.58 | $-0.43 | -42.3% | +2.2% | 3↑ 2↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-0.52 | $-0.62 | $-0.42 | -33.3% | +1.0% | 5↑ 2↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-2.03 | $-2.34 | $-1.75 | -24.7% | +1.8% | 4↑ 3↓ | $0.0B | 0.0% | 10 |
| Next FY 2027-12-31 |
$-2.33 | $-3.07 | $-1.73 | -14.8% | +0.3% | 2↑ 0↓ | $0.0B | 3015.8% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.484 | |
| 7d ago | $-0.495 | +0.011 |
| 30d ago | $-0.495 | +0.011 |
| 60d ago | $-0.498 | +0.014 |
| 90d ago | $-0.456 | -0.028 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 17, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 17, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Feb 27, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Apr 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Mar 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Feb 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Jan 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
EWTX Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings_calendar
EWTX Q1 2026 Earnings Scheduled — 2026-05-06
Apr 6, 2026
short_interest
FTD: EWTX — 37,906 shares ($1.3M) failed to deliver
Settlement: 20260406, Price: $33.33, FTD Value: $1,263,406.98, EDGEWISE THERAPEUTICS INC COM
Mar 30, 2026
Clinical Trial
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: EDG-7500 (Phase 2)
Trial: A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Sponsor: Edgewise Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIV